The human body as a whole performs many adjustments, and the ultimate effect of TRPV1 on PAH may be a combined result of Ca2+, neuropeptides and inflammation, and it may differ according to the concentration of agonists. Here, TRPV1 is linked to pulmonary arterial hypertension.